CMAAO Coronavirus Facts and Myth Buster: Vaccine Tracker

With input from Dr Monica Vasudev

1177 COVID-19 vaccine tracker

  1. To date, only two coronavirus vaccines have been approved. Sputnik V developed by the Gamaleya Research Institute in Moscow was approved by the Ministry of Health of the Russian Federation on August 11.
  2. A second vaccine in Russia, named EpiVacCorona, has also received regulatory approval, also without entering Phase 3 clinical trials.


  Candidate  Type of vaccine  Sponsor   Phase of trial
AZD1222 Replication-deficient viral vector vaccine (chimpanzee adenovirus) The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India Phase 3
BNT162 mRNA-based vaccine Pfizer, BioNTech Phase 3
mRNA-1273 mRNA-based vaccine Moderna Phase 3
Ad5-nCoV Recombinant vaccine (adenovirus type 5 vector) CanSino Biologics Phase 3
CoronaVac Inactivated vaccine (formalin with alum adjuvant) Sinovac Phase 3
Covaxin Inactivated vaccine Bharat Biotech; National Institute of Virology Phase 3
JNJ-78436735 Non-replicating viral vector Johnson & Johnson Phase 3
Name not announced Inactivated vaccine Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) Phase 3
NVX-CoV2373 Nanoparticle vaccine Novavax Phase 3
Sputnik V Non-replicating viral vector Gamaleya Research Institute, Acellena Contract Drug Research and Development Phase 3
BCG vaccine Live-attenuated vaccine University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital Phase 2/3
INO-4800 DNA vaccine (plasmid) Inovio Pharmaceuticals Phase 2/3 Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia
VIR-7831 Plant-based adjuvant vaccine Medicago; GSK; Dynavax Phase 2/3 Medicago
Name not announced Recombinant vaccine Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences Phase 2 Various
ZyCoV-D DNA vaccine (plasmid) Zydus Cadila Phase 2 Zydus Cadila
No name announced Adjuvanted protein subunit vaccine Phase 1/2
AG0301-COVID19 DNA vaccine AnGes, Inc. Phase 1/2 AnGes, Inc.; Japan Agency for Medical Research and Development
BBIBP-CorV Inactivated vaccine Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm) Phase 1/2 Henan Provincial Center for Disease Control and Prevention
EpiVacCorona Peptide vaccine Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Phase 1/2 Federal Budgetary Research Institution State Research Center of Virology and Biotechnology
GX-19 DNA vaccine Genexine Phase 1/2
LNP-nCoVsaRNA Self-amplifying RNA vaccine Imperial College London Phase 1/2
ARCT-021 (LUNAR-COV19) Self-replicating RNA vaccine Arcturus Therapeutics and Duke-NUS Medical School Phase 1/2
Name not announced Protein subunit vaccine Sanofi; GlaxoSmithKline Phase 1/2
No name announced Inactivated vaccine Chinese Academy of Medical Sciences, Institute of Medical Biology Phase 1/2
AdimrSC-2f Protein subunit vaccine Adimmune Phase 1
bacTRL-Spike Monovalent oral vaccine (bifidobacteria) Symvivo Phase 1
COVAX-19 Monovalent recombinant protein vaccine Vaxine Pty Ltd. Phase 1
CVnCoV mRNA-based vaccine CureVac Phase 1
DelNS1-2019-nCoV-RBD-OPT1 Replicating viral vector Xiamen University, Beijing Wantai Biological Pharmacy Phase 1
GRAd-COV2 Adenovirus-based vaccine ReiThera; Leukocare; Univercells Phase 1
UQ-CSL V451 Protein subunit vaccine CSL; The University of Queensland Phase 1
No name announced Adenovirus-based vaccine ImmunityBio; NantKwest Phase 1 Phase 1
SCB-2019 Protein subunit vaccine GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI Phase 1 Linear Clinical Research (Australia)
UB-612 Multitope peptide-based vaccine COVAXX Phase 1 United Biomedical Inc. (UBI)
V590 Recombinant vaccine (vesicular stomatitis virus) Merck; IAVI Phase 1
V591 Measles vector vaccine University of Pittsburgh’s Center for Vaccine Research Phase 1 University of Pittsburgh; Themis Biosciences; Institut Pasteur
VXA-CoV2-1 Recombinant vaccine (adenovirus type 5 vector) Vaxart Phase 1 Vaxart
AAVCOVID Gene-based vaccine Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania Pre-clinical
AdCOVID Intranasal vaccine Altimmune Pre-clinical University of Alabama at Birmingham
ChAd-SARS-CoV-2-S Adenovirus-based vaccine Washington University School of Medicine in St. Louis Pre-clinical Washington University School of Medicine in St. Louis
HaloVax Self-assembling vaccine Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc. Pre-clinical
HDT-301 RNA vaccine University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp Pre-clinical
LineaDNA DNA vaccine Takis Biotech Pre-clinical
MRT5500 Recombinant vaccine Sanofi, Translate Bio Pre-clinical
No name announced Ii-Key peptide COVID-19 vaccine Generex Biotechnology Pre-clinical
No name announced Protein subunit vaccine University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre Pre-clinical
No name announced mRNA-based vaccine Chulalongkorn University’s Center of Excellence in Vaccine Research and Development Pre-clinical
No name announced gp96-based vaccine Heat Biologics Pre-clinical
No name announced Inactivated vaccine Shenzhen Kangtai Biological Products Pre-clinical
PittCoVacc Recombinant protein subunit vaccine (delivered through microneedle array) UPMC/University of Pittsburgh School of Medicine Pre-clinical
T-COVIDTM Intranasal vaccine Altimmune Pre-clinical




Dr KK Aggarwal

President CMAAO, HCFI and Past National President IMA

Be the first to comment

Leave a Reply

Your email address will not be published.